Contribution of amyloid and putative Lewy body pathologies in neuropsychiatric symptoms

Teruyuki Matsuoka; Jin Narumoto; Fukiko Morii-Kitani; Fumitoshi Niwa; Toshiki Mizuno; Mitsunari Abe; Harumasa Takano; Noritaka Wakasugi; Atsushi Shima; Nobukatsu Sawamoto; Hiroshi Ito; Wataru Toda; Takashi Hanakawa; Parkinson's and Alzheimer's disease Dimensional Neuroimaging Initiative

doi:10.1002/gps.5993

Contribution of amyloid and putative Lewy body pathologies in neuropsychiatric symptoms

Int J Geriatr Psychiatry. 2023 Sep;38(9):e5993. doi: 10.1002/gps.5993.

Authors

Affiliations

¹ Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
² Department of Psychiatry, National Hospital Organization Maizuru Medical Center, Kyoto, Japan.
³ Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
⁴ Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
⁵ Human Brain Research Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁶ Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁷ Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima, Japan.
⁸ Department of Neuropsychiatry, Fukushima Medical University, Fukushima, Japan.
⁹ Department of Integrated Neuroanatomy and Neuroimaging, Kyoto University Graduate School of Medicine, Kyoto, Japan.

PMID: 37655505
DOI: 10.1002/gps.5993

Abstract

Objectives: Neuropsychiatric symptom could be useful for detecting patients with prodromal dementia. Similarities and differences in the NPSs between preclinical/prodromal Alzheimer's disease (AD) and prodromal Parkinson's disease dementia (PDD)/Dementia with Lewy bodies (DLB) may exist. This study aimed to compare the NPSs between preclinical/prodromal AD and prodromal PDD/DLB.

Methods: One hundred and three participants without dementia aged ≥50 years were included in this study. The mild behavioral impairment (MBI) total score and the MBI scores for each domain were calculated using the neuropsychiatric inventory questionnaire score. Participants were divided into five groups based on the clinical diagnosis by neurologists or psychiatrists in each institution based on the results of the amyloid positron emission tomography and dopamine transporter single photon emission computed tomography (DAT-SPECT): Group 1: amyloid-positive and abnormal DAT-SPECT, Group 2: amyloid-negative and abnormal DAT-SPECT, Group 3: amyloid-positive and normal DAT-SPECT, Group 4: mild cognitive impairment unlikely due to AD with normal DAT-SPECT, and Group 5: cognitively normal with amyloid-negative and normal DAT-SPECT.

Results: The MBI abnormal perception or thought content scores were significantly higher in Group 1 than Group 5 (Bonferroni-corrected p = 0.012). The MBI total score (Bonferroni-corrected p = 0.011) and MBI impulse dyscontrol score (Bonferroni-corrected p = 0.033) in Group 4 were significantly higher than those in Group 5.

Conclusion: The presence of both amyloid and putative Lewy body pathologies may be associated with psychotic symptoms.

Keywords: Alzheimer's disease; Lewy body disease; amyloid positron emission tomography; dopamine transporter single photon emission computed tomography; mild behavioral impairment; neuropsychiatric symptoms.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / diagnostic imaging
Cognitive Dysfunction*
Dementia*
Humans
Lewy Bodies
Parkinson Disease*

Associated data

UMIN-CTR/UMIN000036297